ACIU Latest Press Releases

-- August 20, 2026 --

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 Globe Newswire 7:00 AM

-- August 11, 2026 --

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson's Disease (PD) Globe Newswire 7:00 AM

-- August 5, 2026 --

AC Immune First Half 2026 Financial and Corporate Update Globe Newswire 7:00 AM

-- July 7, 2026 --

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC 2026 Globe Newswire 7:00 AM

-- June 30, 2026 --

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease Globe Newswire 7:00 AM

-- June 11, 2026 --

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Globe Newswire 7:00 AM

-- May 22, 2026 --

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Globe Newswire 7:00 AM

-- May 12, 2026 --

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Globe Newswire 7:00 AM

-- April 30, 2026 --

AC Immune First Quarter 2026 Financial and Corporate Updates Globe Newswire 7:05 AM

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software